Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma.

"Competing interests The authors declare no competing interests."

"This work was supported by grant from the “Personalized Medicines-Molecular Signature-based Drug Discovery and Development,” and Strategic Priority Research Program of the Chinese Academy of Sciences (XDA12020106), the National Science and Technology Major Project of China (2018ZX09711002-011-006), the Science and Technology Commission of Shanghai Municipality (19431906400), Science and Technology Development Foundation of Shanghai Pudong New Area Health and Family Planning Commission (PW2015E-1), and Shanghai Three-Year Action Plan to Further Accelerate the Development of Traditional Chinese Medicine (ZY3-CCCX-3-3037). The authors are grateful to Ms. Ran-ran Cui for her help and constructive discussions."